Amiodarone induced thyrotoxicosis: Diagnostic and therapeutic strategies
Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic
José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida
Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine
Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: email@example.com
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTAmiodarone causes thyrotoxicosis in 3% of US patients who use it. Two types of amiodarone-induced thyrotoxicosis are recognized, designated type 1 and type 2, based on whether or not the patient had a preexisting thyroid disorder. Distinguishing between the two can be difficult, but it is important for providing appropriate therapy promptly.